Progesterone plays a supporting role in feminizing hormone therapy, primarily helping with breast tissue maturation, testosterone suppression, and potentially sleep. It’s not a standard part of every MTF regimen, and its benefits are still debated among clinicians, but many trans women add it to their estrogen-based therapy for specific reasons.
How Progesterone Works in the Body
Progesterone binds to specific receptors (called PRA and PRB) found across many cell types and organs, where it alters gene expression and changes how cells function. In the context of feminizing hormone therapy, two of its actions matter most: it helps suppress testosterone production, and it contributes to breast tissue development that estrogen alone doesn’t fully achieve.
For testosterone suppression, progesterone influences receptors on the cells in the testes that produce testosterone, reducing its production at the source. It also inhibits the release of luteinizing hormone, a signaling hormone from the brain that tells the body to make testosterone. This makes progesterone a potential complement to estrogen’s own testosterone-lowering effects, though estrogen remains the primary driver of feminization.
Effects on Breast Development
This is the most common reason trans women seek progesterone. Estrogen and progesterone handle different parts of breast growth. Estrogen drives ductal development, which is the branching network of tissue inside the breast. Progesterone drives lobuloalveolar development, the small glandular structures that give breast tissue its mature, full composition. Without progesterone exposure, breast tissue may develop ducts but lack the lobular structures seen in mature cisgender female breasts.
A 2000 histological study by Kanhai and colleagues concluded that progesterone exposure is needed for trans women’s breast tissue to fully mimic the composition of a mature female breast on a cellular level. This finding is often cited as the strongest argument for including progesterone in feminizing therapy.
In terms of actual volume, a 2025 study by Dreijerink and colleagues found that oral progesterone, combined with sufficiently high estradiol levels, increased breast volume by 13 to 37% depending on dosing. However, there’s an important caveat: some of that increase may come from temporary effects like fluid retention and increased blood flow rather than permanent tissue growth. These temporary effects can reverse if progesterone is stopped. The research is still sorting out how much of the size increase represents lasting development versus reversible changes.
One thing progesterone does not appear to do is affect nipple or areolar development. Nipple pigmentation and maturation seem to depend on estrogen levels, not progesterone. Women with complete androgen insensitivity syndrome, who produce estrogen but have limited progesterone receptor activity, often have full breast size but small, pale, underdeveloped nipples, reinforcing that these are estrogen-dependent features.
Sleep, Mood, and Libido
When progesterone is broken down in the body, it produces metabolites that interact with the same brain receptors targeted by anti-anxiety and sleep-promoting compounds. This is why some clinicians recommend taking it at bedtime. Anecdotally, many trans women report improved sleep and a sense of calm after starting progesterone.
The clinical evidence is less clear-cut. A controlled study measuring sleep quality, psychological distress, and breast development in trans women taking low-dose progesterone found no significant changes over three months of follow-up. The researchers noted significant variability between individuals, meaning some people clearly responded while others didn’t. A separate U.S. survey of trans women using progestogens found that relatively few participants reported changes in libido, sleep, or memory. The bottom line: progesterone’s mood and sleep effects are real for some people but far from universal.
When It’s Typically Introduced
Most clinicians who prescribe progesterone don’t start it on day one. The common approach is to introduce it after estrogen has had time to initiate breast development, often after one to two years of feminizing therapy or once breast growth has reached a plateau. The reasoning mirrors puberty in cisgender women, where progesterone levels rise later in development after estrogen has established initial breast tissue.
Some endocrinologists argue progesterone should be a standard part of every trans woman’s regimen from an earlier stage. A perspective published in the Journal of Clinical Endocrinology and Metabolism pointed out that clinical guidelines call for maintaining hormone levels within the normal range for a person’s affirmed gender, and every normal menstrual cycle in cisgender women includes progesterone. By that logic, prescribing estrogen alone doesn’t actually match cisgender female physiology. This view isn’t universally adopted, but it has pushed more clinicians to consider progesterone as part of routine care rather than an optional add-on.
For testosterone suppression specifically, some clinicians recommend daily progesterone (rather than cycling it) at least until orchiectomy, since its anti-gonadotropin effects work continuously. It’s typically taken at bedtime to take advantage of its sleep-promoting properties.
Breast Cancer Risk
The question of whether progesterone increases breast cancer risk in trans women is unresolved but worth understanding. Data from the Netherlands showed increased breast cancer risk in trans women using estrogen combined with cyproterone acetate, a synthetic progestin. This mirrors findings in cisgender women, where combined estrogen-progestin therapy carries higher breast cancer risk than estrogen alone.
The critical distinction is between synthetic progestins and bioidentical (micronized) progesterone. In cisgender women, micronized progesterone appears to carry lower breast cancer risk than synthetic progestins. However, there is essentially no long-term data on micronized progesterone use specifically in trans women. A response published in The BMJ urged caution, noting that in the absence of strong evidence for either improved breast development or cardiovascular outcomes, recommending progesterone as standard therapy may be premature. Most major gender health centers do not include it in their default protocols, though individual prescribers increasingly offer it.
What to Realistically Expect
Progesterone is not a dramatic second puberty. Its effects are subtler than estrogen’s and more variable between individuals. The most consistent benefit supported by evidence is breast tissue maturation at the cellular level, giving breast tissue a composition closer to that of cisgender women. Volume increases are possible but modest, in the range of 13 to 37%, and partially reversible. Sleep improvements happen for some people but not reliably. Libido changes are uncommon. Its contribution to testosterone suppression is real but supplementary to estrogen.
If you’re considering adding progesterone to your regimen, the practical takeaway is that it fills in developmental gaps that estrogen alone may leave, particularly in breast tissue maturity. It’s not a replacement for estrogen, and its benefits accumulate gradually rather than appearing in the first few weeks.